marcus evans europe conferences

R&D Scouting in Pharma: Turning Leads into Value

Fostering Scouting Opportunities on Global Networks to Target the Right Leads, Integrate Robust Evaluation and Prioritization Methodologies and Further Develop the Scalability and Sustainability of Selected Projects

28-30 November 2016
Avenida Palace Hotel, Barcelona, Spain

Why You Should Attend

R&D Scouting in Pharma: Turning Leads into Value

Facing huge changes in its development model, pharmaceutical industry needs to reorganize at large its R&D strategy, to reduce its costs and tap the potential of external innovation. Scouting is becoming crucial as it helps pharma seeking out local promising new biology that can form the basis for innovative drug-discovery programs. But one of the main challenges resides also in transforming promising biology into development potential, scaling up science to long term sustainable projects. Pharma needs to have the right capacities and clear organization structure and tools to accompany and integrate innovation into business, foster research through partnership, entrepreneurship and innovative science hubs.

This marcus evans conference will provide practical case studies on scouting strategies and beyond, in order to select and evaluate research leads, accelerate the process to turn them into value and future projects.  

Key Topics

  • Gain the best practices to connect and engage with external opportunities
  • Develop scouting structure and techniques
  • Enhance internal capability to evaluate and prioritize external assets
  • Develop techniques and methodologies to make your discovery sustainable
  • Benefit from corporate venturing and entrapreneurship
  • Previous Attendees Include

    Eli Lilly and Company, GlaxoSmithKline, AstraZeneca, Pfizer, Unilever, Roche Biologics, Novartis Pharma AG, Abbott Bioresearch Centre, Sanofi-aventis, Boehringer Ingelheim, Johnson & Johnson, Bayer Healthcare, Bristol-Myers Squibb, Daiichi Sankyo Group, Biogen Idec, Genentech, Janssen Pharmaceutical, Merck & Co, Mitsubishi Tanabe Pharmaceuticals, Shire Pharmaceutical

    Why Choose marcus evans?

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.

    Event Partners

    Practical Insights From

    Kristof Van Emelen
    Scientific Director - Partnership Integrator

    Patrick Jimonet
    External Opportunities in early Drug Discovery

    Christophe Cans
    Director, Portfolio Management and Strategic Marketing
    Inserm Transfert

    Dr. Joerg Knaeblein
    Technology Scouting
    Bayer Pharma

    Mary Faris
    Director, CTI West Coast and Australia

    Dr. Michael Woo
    Director, Search & Evaluation Immuno Oncology External Innovation | Global Research & Development
    EMD Serono

    Duncan Holmes
    European Head, Discovery Partnerships with Academia

    Julie Brady
    Business Development Manager for Drug Discovery
    Dundee University

    Click Here For Full Agenda

    Voice of Our Customers
    • “Great. Enjoyed networking” Eisai
    • “Great gathering of professionals in the alliance management” UCB
    • “Overall very good” Merck
    • “Very well organized” Sanofi
    Join the Discussion

    Follow on LinkedIn

    Event Contact

    For all enquiries regarding speaking, sponsoring and attending this conference contact:

    Constandinos Vinall

    marcus evans (Europe) Ltd
    PO Box 24797
    1304 Nicosia, Cyprus

    +357 22849 380
    Fax: +357 22849 394